Ensign Peak Advisors
AERI

Ensign Peak Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

Ensign Peak Advisors’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-36,350
Closed -$273K – 2381
2022
Q2 		$273K Hold
36,350
– – ﹤0.01% 1709
2022
Q1 		$331K Hold
36,350
– – ﹤0.01% 1715
2021
Q4 		$255K Buy
+36,350
New +$380K ﹤0.01% 1869

Other funds holding AERI

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ensign Peak Advisors's AERI Position: Q3 2022 in Review

Ensign Peak Advisors sold out of Aerie Pharmaceuticals (AERI) in Q3 2022, closing a stake of 36,350 shares — an estimated $273K sold.

Ensign Peak Advisors first reported a position in AERI in Q4 2021 and held it in 3 quarters. The position peaked at $331K in Q1 2022. 156 funds tracked by Wall St. Rank hold AERI as of Q3 2022.

  • Ensign Peak Advisors reported no remaining Aerie Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 36,350 Aerie Pharmaceuticals shares in Q3 2022, an estimated $273K.
  • Ensign Peak Advisors first reported a position in Aerie Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Ensign Peak Advisors's Aerie Pharmaceuticals position peaked at $331K in Q1 2022.
  • 156 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2022.

Based on Ensign Peak Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.